Double trouble: Glaucoma and corneal pathology
Oluwatosin U Smith, MD, urges consideration of the interaction between corneal and glaucomatous disease whenever treating glaucoma or corneal issues during the annual Glaucoma 360 meeting in San Francisco, California.
G360 2024: Gene therapy for glaucoma: Great potential but a long way to fruition
A new treatment option may be on the horizon for glaucoma patients.
G360 2024: Rehashing glaucoma treatments with Dr Michael Chaglasian
Optometry Times chats with Michael Chaglasian, OD, FAAO during this year's Glaucoma 360 meeting in San Francisco, California.
G360 2024: Steering patients and ECPs in the right direction regarding driving with glaucoma
Robert L Stamper, MD, raises the question of physician liability for allowing the patient to drive.
G360 2024: Combined MIGS for better IOP efficacy?
Shan C. Lin, MD, discusses combined minimally invasive glaucoma surgery and its impact on achieving improved intraocular pressure efficacy.
G360 2024: One-of-a-kind learning opportunity at the annual event
G360 2023: The fact vs. fiction of OCT test results
Danica Marrelli, OD, FAAO, shares key highlights from her presentation, which she presented during the Glaucoma 360 meeting held this year in San Francisco.
Hypotension: The second modifiable risk factor in glaucoma
According to the Ocular Hypertension Treatment Study, 5 risk factors are associated with high or low risk for primary open-angle glaucoma (POAG), with the intraocular pressure (IOP) historically being the “gold standard” and only modifiable risk factor.
G360 2023: A bird’s eye view of innovation
Kristen Ingenito, MBA, gives key takeaways from her G360 presentation, "A bird’s eye view of innovation."
G360 2023: The latest in IOLs: When and how to use them
Shan Lin, MD, gives key takeaways from his G360 presentation, "The latest in IOLs: When and how to use them?"
G360 2023: Home tonometry: Worth the pressure?
Robert Stamper, MD, gives key takeaways from his G360 presentation, "Home tonometry: Worth the pressure?"
6-month data from first-in-human trials shows promise for bimatoprost-eluting IOL
SpyGlass Pharma presented new data at the Glaucoma 360 New Horizons Forum that supports the use of their proprietary drug delivery platform to lower IOP in patients with glaucoma or ocular hypertension.
New Horizons: Glaucoma challenges of vision restoration
Sustained-release injectables may be key to addressing the greatest obstacles in glaucoma.
G360: MIGS uninhibited: Thinking outside the box
Oluwatosin Smith, MD, reviews different applications of minimally invasive glaucoma surgeries (MIGS) to find the best option, with the best outcome, for every patient.
Identifying and treating glaucoma in high myopes
Risk factors take priority
Glaucoma drugs and drug delivery: Arising from the pandemic
The future is sustained-release injectables
G360: Trends and challenges in glaucoma
Andrew G. Iwach, MD, shares a few key highlights from his presentation regarding trend challenges of glaucoma.
The glaucoma market: Rapid sustained expansion driven by novel devices, drugs
Industry keenly focused on innovations
G360: New Horizons: Technologies for the future of eyecare
Ranya Habash, MD, shares a sneek peek of her New Horizions keynote speech on "The future of eye care: science fiction to science fact," during the 2022 Glaucoma 360 meeting.
What to expect from this year's Glaucoma 360 meeting
Glaucoma 360's co-founders and co-chairs Andrew G. Iwach, MD, and Adrienne L. Graves, PhD, offer a sneak peek on what attendees can expect from this year's annual meeting.
2 Commerce Drive Cranbury, NJ 08512